Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressured Regeneron from all-time highs, and the firm sees its current share price at a “particularly attractive entry point, with limited downside risk.” Wolfe adds that its bullish take hinges on belief that in 2025, peer-leading growth, through either successful launches or defensive positioning, will be rewarded.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron initiated with an Outperform at Wolfe Research
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Regeneron initiated with a Neutral at Citi
- Regeneron announces new, updated data from hematology pipeline at ASH
- Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer